scholarly journals Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study

2016 ◽  
Vol 138 (1) ◽  
pp. 162-168 ◽  
Author(s):  
François Spertini ◽  
Gilles DellaCorte ◽  
Alexander Kettner ◽  
Frédéric de Blay ◽  
Lars Jacobsen ◽  
...  
Keyword(s):  
Specific Immunotherapy ◽  
Allergic Rhinoconjunctivitis ◽  
Allergen Specific Immunotherapy ◽  
Bet V 1

scholarly journals A comparison of different methods of the allergen-specific immunotherapy in patients with pollinosis: the results of open randomized study

2019 ◽  
Vol 16 (3) ◽  
pp. 35-45
Author(s):  
A Y Nasunova ◽  
N M Nenasheva
Keyword(s):  
Pollen Season ◽  
Specific Immunotherapy ◽  
Allergic Rhinoconjunctivitis ◽  
Nasal Lavage ◽  
Subcutaneous Immunotherapy ◽  
Immune Reactivity ◽  
Allergen Specific Immunotherapy ◽  
New Findings ◽  
Study Results ◽  
Specific Igg4

Background. Allergen-specific immunotherapy (ASIT) is viewed as the only treatment that influences all patho-genetically significant parts of the allergic process in the initial and late phases of the IgE-mediated allergic reaction and modifies the abnormal immune reactivity to a specific allergen. Currently, sublingual (SLIT) and subcutaneous (SCIT) immunotherapy are most commonly used in clinical practice. Despite long experience of sublingual and subcutaneous immunotherapy application, questions remain about the preferred ASIT method and comparative effectiveness of different ASIT methods. This article evaluates the efficacy, benefits of SCIT and SLIT and highlights new findings related mechanisms and potential biomarkers. The aim of the study. To evaluate the comparative efficacy of different methods of ASIT (subcutaneous and sublingual) based on clinical data and biomarkers in the blood serum and other biological fluids in adult patients with allergic rhinoconjunctivitis (with/without asthma). Materials and methods. 60 patients with allergic rhinoconjunctivitis (with/without asthma) aged 18 to 50 were randomly assigned to 3 groups treated by sublingual immunotherapy with extracts of allergens, subcutaneous immunotherapy with extracts of allergens and subcutaneous with modified allergens (allergoids) respectively. Results. The efficiency of the first course of preseason ASIT (SCIT and SLIT) with extracts of allergens and aller-goids in the control of symptoms of allergic rhinoconjunctivitis (with/without asthma) was demonstrated. After the end of the first year pre-season ASIT data analysis scales (Total Symptom Score -TSS, Medircation Score -MS) revealed the best performance in the group of patients receiving SCIT with allergoids compared with patients receiving the SLIT with extracts of allergens: the scales of the TSS (p=0.023), MS (p=0.002). In addition, at the end of the maintenance phase of ASIT in patients treated with SCIT with allergoids the level of eosinophilic cationic protein (ECP) in the nasal lavage decreased by 22% (p=0.012), secretory immunoglobulin A (sIgA) in the nasal lavage increased by 70% (p=0.001), interleukin-10 (IL-10) in serum increased by 126% (p=0.006), allergen-specific IgG4 increased by 42% (p=0.01) from the initial values, that correlates with a decrease in the severity of clinical manifestations. In pollen season ECP level in nasal lavage was significantly (p=0.007) lower in a group of patients who received SCIT with allergoids compared with patients who received the SLIT with extracts of allergens. The most significant changes of serum level of IL-10 in the pollen season occurred in a group of patients receiving SCIT with allergoids compared with patients who received SLIT (p=0.013) and SCIT (p=0.001) with extracts of allergens. Conclusion. The study results deepen the existing understanding of the mechanisms of SCIT and SLIT. They allow to develop a comprehensive assessment of the therapy efficacy scheme based on clinical parameters and on monitoring of local (ECP, sIgA) and systemic biomarkers (IL-10, allergen-specific IgG4) as well.

scholarly journals Soluble trail as a marker of efficacy of allergen-specific immunotherapy in patients with allergic rhinoconjunctivitis

2012 ◽  
Vol 18 (10) ◽  
pp. CR617-CR621 ◽  
Author(s):  
Arzu Didem Yalcin ◽  
Saadet Gumuslu ◽  
Gizem Esra Parlak ◽  
Atil Bısgın
Keyword(s):  
Specific Immunotherapy ◽  
Allergic Rhinoconjunctivitis ◽  
Allergen Specific Immunotherapy ◽  
Soluble Trail

Characterization of a Hypoallergenic Recombinant Bet v 1 Variant as a Candidate for Allergen-Specific Immunotherapy

2007 ◽  
Vol 145 (3) ◽  
pp. 193-206 ◽  
Author(s):  
H. Kahlert ◽  
R. Suck ◽  
B. Weber ◽  
A. Nandy ◽  
M. Wald ◽  
...  
Keyword(s):  
Specific Immunotherapy ◽  
Allergen Specific Immunotherapy ◽  
Bet V 1

IgE and allergen-specific immunotherapy-induced IgG4recognize similar epitopes of Bet v 1, the major allergen of birch pollen

2016 ◽  
Vol 47 (5) ◽  
pp. 693-703 ◽  
Author(s):  
N. Groh ◽  
C. S. von Loetzen ◽  
B. Subbarayal ◽  
C. Möbs ◽  
L. Vogel ◽  
...  
Keyword(s):  
Specific Immunotherapy ◽  
Birch Pollen ◽  
Major Allergen ◽  
Allergen Specific Immunotherapy ◽  
Bet V 1

scholarly journals Efficacy of allergen-specific immunotherapy with «Phostal» in seasonal allergic rhinoconjunctivitis

2009 ◽  
Vol 6 (3) ◽  
pp. 58-64
Author(s):  
Oksana Mikhaylovna Kurbacheva ◽  
K S Pavlova ◽  
N I Il'ina ◽  
I V Andreev ◽  
N L Ryabova ◽  
...  
Keyword(s):  
Specific Immunotherapy ◽  
Allergic Rhinoconjunctivitis ◽  
Allergen Specific Immunotherapy

scholarly journals The influence of subcutaneous allergen-specific immunotherapy with birch extract absorbed onto calcium phosphate on quality of life of children with allergic rhinoconjunctivitis: 2-years follow-up results

2014 ◽  
Vol 11 (1) ◽  
pp. 33-38
Author(s):  
N V Shakhova ◽  
U F Lobanov ◽  
V V Gordeev ◽  
V P Tokarev ◽  
M V Surkova
Keyword(s):  
Quality Of Life ◽  
Calcium Phosphate ◽  
Specific Immunotherapy ◽  
Systemic Reaction ◽  
Allergic Rhinoconjunctivitis ◽  
Control Group ◽  
Allergen Specific Immunotherapy ◽  
Local Reactions

Background. The purpose of the study was to investigate the influence of subcutaneous allergenspecific immunotherapy with birch extract absorbed onto calcium phosphate on quality of life of children with allergic rhinoconjunctivitis Methods. 50 patients at the age from 5 to17 years old with allergic rhinoconjunctivitis sensitized to trees pollen (birch, alder, hazel) were observed. All the patients were divided into 2 groups. The first group consisted of 23 children, who were treated with birch extract («Phostal») subcutaneous allergen-specific immunotherapy (SCIT). The second group was a control group, consisted of 27 children, no treatment was assigned to them. Results. Statistically significant increase of all quality of life indexes in the group which was treated with SCIT using «Phostal» was observed. Statistically valid decrease of severity of rhinoconjunctivitis symptoms in the 1 group was shown (6,1±3,1; 11,8±4,5; p=0,00002). Total number of Phostal injections was 990, 227 (23%) local reactions and no one systemic reaction have been observed during the study. Conclusion. SCIT with birch extract absorbed onto calcium phosphate could be considered as a highly effective and safe method of treatment of pollinosis in children.

Sign in / Sign up

Export Citation Format

Share Document